![Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports](https://casereports.bmj.com/content/casereports/2016/bcr-2016-216448/F3.large.jpg)
Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports
![SimMK on X: "Mocking different stages of Phlebitis using #moulage techniques to enhance our IV study day. https://t.co/Y91JImQhN7" / X SimMK on X: "Mocking different stages of Phlebitis using #moulage techniques to enhance our IV study day. https://t.co/Y91JImQhN7" / X](https://pbs.twimg.com/media/C2W-EiuWIAEgZNX.jpg:large)
SimMK on X: "Mocking different stages of Phlebitis using #moulage techniques to enhance our IV study day. https://t.co/Y91JImQhN7" / X
![Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports](https://casereports.bmj.com/content/casereports/2016/bcr-2016-216448/F1.large.jpg)
Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports
![Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports](https://casereports.bmj.com/content/casereports/2016/bcr-2016-216448/F2.large.jpg)
Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients | BMJ Case Reports
![A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis | Semantic Scholar A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4dc8eeec3ef4d44b96cd0c607586d695e9c36556/4-Figure2-1.png)